Valuation: Pacific Software, Inc.

Market Cap 48.82M 42.88M 39.88M 36.59M 68.76M 4.7B 69.82M 474M 185M 2.31B 183M 179M 7.99B P/E 2019
-2.65x
P/E 2020 -41.2x
Enterprise Value 49.19M 43.2M 40.18M 36.87M 69.27M 4.74B 70.34M 477M 186M 2.33B 185M 181M 8.05B EV / Sales 2019
-
EV / Sales 2020 2,435,972,350x
Free-Float
99%
Yield 2019 *
-
Yield 2020 -
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2026-06-09
Director TitleAgeSince
Chairman 74 2016-10-21
Change 5-day change 1-year change 3-year change Capi.($)
-22.83%-.--% - - 3.12M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.25%+1.65%+408.41%+629.49% 40.13B
-0.27%+4.45%+9.93%+66.92% 36.33B
+0.35%+0.87%+3.60%-8.81% 34.6B
+3.14%+1.02%+3.37%+38.15% 26.77B
+0.47%-2.74% - - 16.66B
-0.73%+11.84%+31.97%+143.53% 16.91B
+0.42%-5.52%+0.76%+8.50% 13.05B
-2.68%-2.49%-15.00%-31.68% 13.05B
Average -2.08%+0.99%+54.97%+107.37% 27.09B
Weighted average by Cap. +0.46%+1.10%+75.57%+137.02%

Financials

2019 2020
Net sales - 0.02 0.02 0.02 0.01 0.03 1.93 0.03 0.19 0.08 0.95 0.08 0.07 3.27
Net income -21.11M -18.54M -17.24M -15.82M -29.73M -2.03B -30.19M -205M -80M -1B -79.25M -77.55M -3.46B -1.17M -1.03M -959K -880K -1.65M -113M -1.68M -11.39M -4.45M -55.6M -4.41M -4.31M -192M
Net Debt -101K -88.32K -82.13K -75.37K -142K -9.68M -144K -975K -381K -4.76M -377K -369K -16.46M 367K 323K 300K 275K 517K 35.39M 525K 3.56M 1.39M 17.4M 1.38M 1.35M 60.15M
Logo Pacific Software, Inc.
PurMinds Enterprises, Inc., formerly Pacific Software, Inc., is a precision neuro-medicine development company pursuing solutions to neurological and psychiatric disorders. The Company's clinical pipeline includes neuroprotective compounds that restore neuronal functions and can address multiple clinical indications with significant unmet patient needs. The Company is focused on a 4P Medicine platform, in strategic partnership with SpectroChip Global Inc., for early detection and intervention of conditions before irreversible damage occurs. The Company operates under a Health Canada issued Controlled Drugs and Substances License. It has developed a pipeline of proprietary formulations and novel small molecules (NCEs). The Company's pipeline includes PUR100 Series and PUR500 Series.
Employees
-